- Biogen, headquartered in Cambridge, Massachusetts, is a leading biotechnology company focused on developing therapies for neurological diseases and has recently reported a revenue of $2.8 billion in Q2 2025, reflecting a 7% growth driven by new product launches and its U.S. multiple sclerosis (MS) business.
- In March 2026, Biogen announced its acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, which will enhance its portfolio in immunology and rare diseases by adding two FDA-approved products, EMPAVELI® and SYFOVRE®.
- Biogen's recent product launches, including VUMERITY for MS, have contributed to significant revenue growth, with launch products generating $252 million in Q2 2025, marking a 91% year-over-year increase.
- Biogen's ideal buyers include healthcare providers and institutions treating neurological and rare diseases, as their products address critical unmet needs in these areas, making it a pivotal time for sales teams to engage with Biogen given their expanding product portfolio and market presence.
Biogen's workforce is organized across 19 departments, with a significant concentration in Operations, which employs 955 individuals. Information Technology follows closely with 586 employees, while the Executive department comprises 540 staff members. This distribution indicates a strong emphasis on operational efficiency and technological support, reflecting the company's commitment to innovation in the pharmaceutical sector.
The company's workforce is primarily concentrated in Cambridge, Massachusetts, which houses 1,771 employees, making it the largest location. Other notable locations include Weston, MA, with 245 employees, and Durham, NC, with 99 employees. The 'Other' category accounts for a substantial 2,776 employees, indicating a distributed workforce across various regions, enhancing Biogen's operational flexibility and reach.
